Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPPIK pediatric sparsentan study in proteinuric glomerular diseases
NL-OMON52074Phase 2Recruiting
- Sponsor
- Travere Therapeutics
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sparsentan in focal segmental glomerulosclerosis (FSGS), nephrosis, IgA nephropathy (IgAN) and 3 more (3 arms), sponsored by Travere Therapeutics. Primary endpoints: Safety and tolerability and Change in proteinuria. Started Nov 2023; status: recruiting.
02
Drugs
sparsentan
03
Conditions
focal segmental glomerulosclerosis (FSGS)nephrosisIgA nephropathy (IgAN)Henoch-Schönlein Purpura (HSP)Alport syndrome
Beyond the preview
Go deeper on NL-OMON52074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52074.